Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2013; 19(46): 8703-8708
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8703
Figure 1
Figure 1 Flow chart of type 3 gastric neuroendocrine tumors. Of all type 3 gastric neuroendocrine tumors (NETs) (n = 119), 39 patients were treated with surgery, 50 patients were treated using an endoscopic method, and 15 patients were followed up only by observation. In the endoscopic treatment group, 41 patients were treated with endoscopic mucosal resection (EMR), and nine patients were treated with endoscopic submucosal dissection (ESD). Upon analysis of the resected specimens, histologically incomplete resections were found in seven cases in the EMR group and three cases in the ESD group, and lymphovascular invasion was found in one case in the EMR group and two cases in the ESD group. All cases of lymphovascular invasion were treated with an additional operation. During the median follow-up duration (46 mo), there was no recurrence of gastric NETs in the endoscopic resection group.